Scarica l'app Stockscreener
12.53
4.42%
0.53
Dopo l'orario di chiusura:
12.62
0.09
+0.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AUPH Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$12.00
Aprire:
$12
Volume 24 ore:
2.28M
Relative Volume:
1.19
Capitalizzazione di mercato:
$1.65B
Reddito:
$260.11M
Utile/perdita netta:
$60.64M
Rapporto P/E:
29.14
EPS:
0.43
Flusso di cassa netto:
$92.29M
1 W Prestazione:
+3.73%
1M Prestazione:
+9.43%
6M Prestazione:
+55.07%
1 anno Prestazione:
+79.51%
Intervallo 1D:
$11.99
$12.64
Intervallo di 1 settimana:
$11.57
$12.64
Portata 52W:
$6.42
$12.64
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Nome
Aurinia Pharmaceuticals Inc
Settore
Industria
Telefono
250-744-2487
Indirizzo
#140, 14315 - 118 AVENUE, EDMONTON, BC
Confronta AUPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
12.53 | 1.54B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-04 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-05-05 | Iniziato | Cowen | Outperform |
| 2020-01-10 | Iniziato | Jefferies | Buy |
| 2019-12-16 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-16 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-10-30 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Reiterato | FBR & Co. | Outperform |
| 2016-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2016-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2015-05-08 | Iniziato | MLV & Co | Buy |
Mostra tutto
Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie
Can a trend reversal in Aurinia Pharmaceuticals Inc. lead to recovery2025 Major Catalysts & Fast Gain Swing Trade Alerts - Newser
Published on: 2025-09-03 06:23:23 - Newser
Analyzing Aurinia Pharmaceuticals Inc. with risk reward ratio chartsDividend Hike & Smart Money Movement Alerts - Newser
Will Aurinia Pharmaceuticals Inc. bounce back from current support2025 Technical Patterns & Safe Entry Momentum Stock Tips - Newser
What Fibonacci levels say about Aurinia Pharmaceuticals Inc. rebound2025 Year in Review & Scalable Portfolio Growth Ideas - Newser
Applying Elliott Wave Theory to Aurinia Pharmaceuticals Inc.July 2025 PostEarnings & High Yield Stock Recommendations - Newser
How to integrate Aurinia Pharmaceuticals Inc. into portfolio analysis tools2025 Pullback Review & Stock Portfolio Risk Management - Newser
Is Aurinia Pharmaceuticals Inc. showing insider buyingTrade Volume Report & Stock Timing and Entry Methods - khodrobank.com
How sentiment analysis helps forecast Aurinia Pharmaceuticals Inc.July 2025 Catalysts & Smart Allocation Stock Reports - Newser
Can machine learning forecast Aurinia Pharmaceuticals Inc. recoveryJuly 2025 Review & Technical Pattern Alert System - Newser
Can Aurinia Pharmaceuticals Inc. grow without external fundingWeekly Stock Report & Weekly High Conviction Ideas - khodrobank.com
Using economic indicators to assess Aurinia Pharmaceuticals Inc. potentialPortfolio Risk Summary & Technical Pattern Based Buy Signals - Newser
Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm - Barchart.com
Real time alert setup for Aurinia Pharmaceuticals Inc. performanceTake Profit & Real-Time Chart Pattern Alerts - Newser
Will Aurinia Pharmaceuticals Inc. benefit from government policyWeekly Market Report & Free Technical Pattern Based Buy Signals - khodrobank.com
Is Aurinia Pharmaceuticals Inc. gaining market share2025 Top Decliners & Low Risk High Win Rate Stock Picks - khodrobank.com
What is Aurinia Pharmaceuticals Inc.’s market position2025 Market WrapUp & Verified Momentum Watchlists - khodrobank.com
Aurinia Pharmaceuticals Inc. stock trend outlook and recovery pathBond Market & Weekly Momentum Stock Picks - Newser
Published on: 2025-09-02 04:45:19 - Newser
Published on: 2025-09-02 10:21:51 - Newser
Advanced analytics toolkit walkthrough for Aurinia Pharmaceuticals Inc.Treasury Yields & Technical Analysis for Trade Confirmation - Newser
Multi factor analysis applied to Aurinia Pharmaceuticals Inc.July 2025 Reactions & Free Growth Oriented Trading Recommendations - Newser
What are Aurinia Pharmaceuticals Inc.’s technical support levelsJuly 2025 Sector Moves & Smart Money Movement Tracker - khodrobank.com
How does Aurinia Pharmaceuticals Inc. compare to its peersDividend Hike & Step-by-Step Swing Trade Plans - khodrobank.com
Can Aurinia Pharmaceuticals Inc. sustain earnings growthMarket Sentiment Summary & Weekly Breakout Stock Alerts - khodrobank.com
What makes Aurinia Pharmaceuticals Inc. stock attractive today2025 Top Decliners & Real-Time Price Movement Reports - khodrobank.com
Does Aurinia Pharmaceuticals Inc. offer margin of safetyMarket Risk Analysis & Real-Time Price Movement Reports - khodrobank.com
Aurinia Pharmaceuticals Inc. Reversal Rally May Surprise Bears getLinesFromResByArray error: size == 0 - kangso.co.kr
Can Aurinia Pharmaceuticals Inc. hit a new high this monthMarket Performance Recap & Reliable Price Breakout Alerts - Newser
Is Aurinia Pharmaceuticals Inc. forming a bottoming baseTrade Volume Summary & Weekly High Momentum Picks - Newser
Using data filters to optimize entry into Aurinia Pharmaceuticals Inc.Market Trend Review & Reliable Entry Point Alerts - Newser
Aurinia Pharmaceuticals Inc. stock retracement – recovery analysis2025 Performance Recap & High Conviction Investment Ideas - Newser
News impact scoring models applied to Aurinia Pharmaceuticals Inc.2025 Institutional Moves & Weekly High Return Stock Forecasts - Newser
What data driven models say about Aurinia Pharmaceuticals Inc.’s futureEarnings Growth Summary & Consistent Return Strategy Ideas - Newser
Aurinia Pharmaceuticals Inc Azioni (AUPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aurinia Pharmaceuticals Inc Azioni (AUPH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
| Keenan Greg | Chief Medical Officer |
Mar 07 '25 |
Sale |
8.23 |
8,305 |
68,350 |
153,484 |
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):